Shanghai NovelBio Pharmaceutical Technology Co., Ltd.

As a nationally certified high-tech enterprise, NovelBio is dedicated to life science research and applied development, specializing in cutting-edge next-generation sequencing (NGS) and bioinformatics solutions. Our integrated portfolio spans scientific services, bioinformatics analysis, equipment/reagent manufacturing, and translational medicine, providing comprehensive support to global research institutions, medical centers, and biopharmaceutical companies.

We deliver a complete suite of advanced genomic services including single-cell sequencing, spatial transcriptomics, Xenium in-situ spatial omics, and conventional transcriptome sequencing. To date, our platforms have empowered over 600 universities and hospitals, supported 5,000+ collaborative researchers, and contributed to 10,000+ research projects—including 300+ publications in top-tier journals (CNS series). Single-cell multi-omics publications show consistent annual growth, with >60% of supported studies achieving impact factors ≥10 across fields including oncology, neuroscience, COVID-19 research, and developmental biology.

Looking ahead, NovelBio will continue to pioneer single-cell technological innovation, driving synergy across technology, clinical application, and industry development. We are building an integrated ecosystem for life health sciences, delivering end-to-end solutions while contributing China's expertise to global scientific advancement and human health.